At present, prognosis and treatment stratification is based on clinical stage, histologic evaluation with a Gleason grade as a measure of tumor differentiation, and serum prostate-specific antigen (PSA) levels, which do not accurately predict clinical outcome [4,5]. The gene discussed is KLK3; the disease is neoplasm.